Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9480	Companies
185554	Keywords
117943	Articles
99386	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 05/21/2025 at 14:05, 6 months 15 days ago

Jaguar Health Conducts $1.5M Registered Direct Offering

Private Placement Nasdaq Jaguar Health Common Stock Direct Offering
PRESS RELEASE

published on 05/21/2025 at 14:00, 6 months 15 days ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces purchase of 246,306 shares of common stock at $6.09 per share in a registered direct offering. H.C. Wainwright & Co. serves as exclusive placement agent

Shares Stock Purchase Jaguar Health H.C. Wainwright & Co. Direct Offering
BRIEF

published on 05/20/2025 at 15:20, 6 months 16 days ago

Jaguar Health Begins Phase 2 Trial for Crofelemer in Pediatric MVID Patients

Crofelemer Jaguar Health Phase 2 Trial MVID Pediatric Treatment
BRIEF

published on 05/20/2025 at 15:20, 6 months 16 days ago

Jaguar Health lance un essai de phase 2 pour le Crofelemer chez les patients pédiatriques atteints de MVID

Crofelemer Jaguar Health Essai De Phase 2 MVID Traitement Pédiatrique
PRESS RELEASE

published on 05/20/2025 at 15:15, 6 months 16 days ago

First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Jaguar Health's crofelemer shows promise in reducing total parenteral support in pediatric MVID patient. Ongoing trials and future expectations discussed

Crofelemer Clinical Trials Jaguar Health Pediatric MVID Total Parenteral Support
BRIEF

published on 05/19/2025 at 16:42, 6 months 17 days ago

Jaguar Health Inc. reçoit une note d'achat de First Berlin Equity Research

Crofelemer Jaguar Health Approbation De La FDA Acheter Une Note Potentiel De Croissance
BRIEF

published on 05/19/2025 at 16:42, 6 months 17 days ago

Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research

Crofelemer FDA Approval BUY Rating Jaguar Health Growth Potential
PRESS RELEASE

published on 05/19/2025 at 16:37, 6 months 17 days ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Jaguar Health Inc, recommending a Buy with USD 60.00 price target. Jaguar focuses on plant-based medicines for GI health challenges, with crofelemer as flagship product

Jaguar Health Inc First Berlin Equity Research BUY Rating Plant-based Medicines GI Health Challenges
BRIEF

published on 05/15/2025 at 20:35, 6 months 21 days ago

Jaguar Health annonce une baisse de son chiffre d'affaires au premier trimestre 2025

Baisse Des Revenus Produits Sur Ordonnance Réunion De La FDA Résultats Financiers Du Premier Trimestre 2025 Croissance De Mytesi
BRIEF

published on 05/15/2025 at 20:35, 6 months 21 days ago

Jaguar Health Reports Decreased Revenue in Q1 2025

Revenue Decline Prescription Products FDA Meeting Q1 2025 Financials Mytesi Growth

Accesswire

Published on 12/05/2025 at 21:20, 11 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 31 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 1 hour 6 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 1 hour 16 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 41 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 2 hours 33 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 3 hours 5 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 3 hours 16 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 3 hours 39 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 3 hours 45 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 4 hours 13 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 4 hours 13 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 6 hours 20 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 6 hours 20 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 33 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE